10-K · March 16, 2026
Standard BioTools positions itself as a focused life‑science tools company concentrating on mass cytometry, spatial biology and genomics after divesting its SomaScan aptamer/proteomics business. The 10‑K documents a…
Earnings analysis · 10-Q
LAB earnings analysis
Filed May 6, 2026 · Our reading of the company's report
The latest report
Standard BioTools reported a Q1 2026 revenue of $21.15M, up 5% year-over-year, significantly exceeding analyst expectations of $17.75M. However, despite this revenue growth, the company posted a loss per share of…
Read full summary
Standard BioTools reported a Q1 2026 revenue of $21.15M, up 5% year-over-year, significantly exceeding analyst expectations of $17.75M. However, despite this revenue growth, the company posted a loss per share of -$0.04, missing estimates and reflecting ongoing operational challenges exacerbated by restructuring efforts.
Gross and operating margin
How much of each revenue dollar the business keeps.
One point per quarterly or annual filing. Both margins are shares of that report's revenue.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
Reported figures
- Earnings per share
- $-0.04
- Gross margin
- 53.5%
What stood out
-
Revenue Exceeds Expectations
Actual revenue of $21.15M surpassed estimates of $17.75M, reflecting a 5% increase year-over-year.
-
Gross Margin Holds Steady
Gross margin was reported at 53.5%, slightly down from 54.6% in the prior year.
-
Significant R&D Cost Reduction
R&D expenses dropped by 61%, from $5.44M to $2.12M, attributed to restructuring.
-
Substantial Reduction in SG&A
SG&A expenses decreased by 38%, from $29.82M to $18.61M, improving operational efficiency.
-
Cash Position Strengthened
Cash, cash equivalents, and investments increased to $526.5M from $213.3M, bolstered by the sale of the SomaScan Business.
-
Positive Cash Flow from Investing Activities
Net cash provided by investing activities was $191.1M, driven largely by the proceeds from the SomaScan divestiture.
What to watch
-
Ongoing Nasdaq Compliance Risk
The company received a notice from Nasdaq for falling below the $1.00 minimum bid price requirement for listing.
-
Negative Operating Cash Flow
Operating activities resulted in a cash outflow of $46.6M, an increase from $30.3M year-over-year.
-
Dependency on Future Capital Raises
The company admitted that its liquidity depends significantly on maintaining revenue levels and access to funding.
Management's outlook
2026 revenue guidance lowered to $70M-$75M from previous estimates of $80M-$85M.
Earlier filings 4
10-Q · November 4, 2025
Standard BioTools reported Q3 revenue of $19.552M, down from $22.086M in Q3 2024, while GAAP net loss widened to $34.687M (EPS -$0.09). Gross margin compressed to 48.5% and operating loss widened as operating expenses…
10-Q · August 15, 2025
Standard BioTools reported continuing-operations revenue of $21,762 (thousands) for Q2 2025, down from $22,492 in Q2 2024, while gross margin improved to 48.8% and operating loss narrowed. The company classified the…
10-K · March 11, 2025
Standard BioTools reported a mixed performance in its latest 10-K filing for the fiscal year ending December 31, 2024. The company experienced a revenue increase, aided by key acquisitions including SomaLogic, but…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.